MAZE · Maze Therapeutics, Inc. · Executive Compensation
$26.43
+0.00 (+0.00%)
At close · Oct 5
Return incl. dividend (before tax)
Market Cap
$1.45B
Shares
55.55M
Volume · Oct 5
588.03K
Avg daily vol (3M)
563.83K
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
No Compensation Data
No Summary Compensation Table has been imported from this company's proxy statements yet.
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Hervé Hoppenot | Class III director | Appointed | 2026-08-17 |
| Hervé Hoppenot | Class II director | Resigned | 2026-08-17 |
| Nancy C. Andrews, M.D., Ph.D. | Class II director | Appointed | 2026-08-17 |
| Nancy C. Andrews, M.D., Ph.D. | Class III director | Resigned | 2026-08-17 |
| Sophie Kornowski, Pharm.D. | Class I director | Appointed | 2026-08-17 |
| Paula A. Johnson, M.D., M.P.H. | Class III director | Appointed | 2026-08-17 |
| Amy Bachrodt | Senior Vice President, Finance | Resigned | 2026-05-22 |
| Neil Kumar | Class I director | Appointed | 2026-03-25 |
| Hervé Hoppenot | Class II director | Appointed | 2025-10-06 |
| Hervé Hoppenot | Chairman of the Board | Appointed | 2025-10-06 |
| Misbah Tahir | Chief Financial Officer and "principal financial officer" | Appointed | 2025-09-02 |